Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Cancer Immunol Immunother. 2015 May 22;64(9):1095–1108. doi: 10.1007/s00262-015-1712-6

Fig. 2.

Fig. 2

Treatment-induced changes in splenocyte T cell populations and immune gene expression profiles. A Heat map of top 20 DE genes (adjusted q<0.05) in splenocytes of MUC1.Tg mice that received anti-PD-L1 or rat IgG (controls), detected via Nanostring. B Top five canonical pathways identified by IPA, using n=79 DE genes. C Phenotypic analysis via flow multicolor cytometry of splenocytes from mice treated with either anti-PD-L1 or control rat IgG. Percent cells positive for CD3 (left), CD4 (middle) and CD8 (right) are shown. D Flow cytometry dot plots showing intracellular staining for IFNγ and LAMP1 following ex-vivo stimulation of whole splenocytes in anti-CD3 coated 96 well plates. Data shown is from one representative mouse from either the isotype control (left) or anti-PD-L1 treatment group (right). E Total counts for CD8+ T cells expressing the degranulation marker LAMP1 (CD107a) from n=5 control treated and n=6 anti-PD-L1 treated mice. * p<0.05; ** p<0.001, Mann Whitney t test.